Financial Performance - For the nine months ended December 31, 2019, the company reported a total revenue of HKD 38,562,000, a slight increase from HKD 38,591,000 in the same period of 2018[5] - The company incurred a loss of HKD 2,154,000 for the nine months ended December 31, 2019, compared to a loss of HKD 5,796,000 in the same period of 2018, indicating an improvement in performance[5] - Basic and diluted loss per share for the nine months ended December 31, 2019, was HKD 0.19, compared to HKD 0.64 for the same period in 2018[5] - The company reported a total comprehensive loss attributable to owners of the company of HKD 931,000 for the nine months ended December 31, 2019, compared to HKD 1,268,000 in the same period of 2018[5] - The company recorded a loss attributable to owners of approximately HKD 0.9 million for the nine months ended December 31, 2019, a decrease of about 71.0% compared to a loss of approximately HKD 3.1 million for the same period in 2018[48] - The basic loss per share for the nine months ended December 31, 2019, was HKD 0.19, a reduction of approximately 70.3% from HKD 0.64 for the same period in 2018[48] Revenue Breakdown - The company’s revenue is generated from diagnostic services, prescription and dispensing services, and skincare treatments[34] - For the nine months ended December 31, 2019, the total revenue was approximately HKD 38.6 million, with diagnostic services, prescription and dispensing services, and treatment services contributing approximately HKD 1.2 million, HKD 11.8 million, and HKD 25.6 million, respectively, accounting for 3.1%, 30.7%, and 66.2% of total revenue[47] Operating Expenses - Total operating expenses for the nine months ended December 31, 2019, were HKD 7.86 million, down from HKD 16.17 million in the previous year[37] - The company’s employee costs for the nine months ended December 31, 2019, were HKD 18,453,000, compared to HKD 19,044,000 in the same period of 2018, showing a reduction[5] - Other expenses decreased by approximately HKD 8.3 million, or 51.2%, to HKD 7.9 million for the nine months ended December 31, 2019, attributed to reduced rental expenses and marketing costs[60] - The company’s other operating expenses included property rental and related expenses of HKD 1.31 million for the nine months ended December 31, 2019[37] Lease and Asset Management - The company recognized right-of-use assets amounting to HKD 20,390,000 and lease liabilities of HKD 20,022,000 upon the initial application of HKFRS 16 on April 1, 2019[32] - The company applied the short-term lease exemption for leases with a term of 12 months or less and for low-value asset leases, recognizing lease payments as expenses on a straight-line basis[15] - The company measures lease liabilities at the present value of unpaid lease payments, using the incremental borrowing rate if the implicit rate is not readily determinable[22] - The company will adjust lease liabilities and related right-of-use assets if there are changes in lease terms or assessments regarding purchase options[26] Corporate Governance and Shareholding - The audit committee, consisting of three independent non-executive directors, reviewed the unaudited consolidated financial statements for the nine months ended December 31, 2019, ensuring compliance with applicable accounting standards[80] - The company has complied with the corporate governance code as per GEM listing rules during the nine months ended December 31, 2019[73] - Topline holds a beneficial ownership of 274,865,400 shares, representing 56.59% of the issued share capital[69] - 富麒控股有限公司, 富麒, holds 80,000,000 shares, accounting for 16.47% of the issued share capital[69] - Magnolia Wealth International Limited and Mr.季昌群 each hold 80,000,000 shares, also representing 16.47% of the issued share capital[69] Future Outlook - The company will continue to focus on introducing new services and products to maintain competitiveness and explore new business opportunities in response to economic challenges[51]
密迪斯肌(08307) - 2020 Q3 - 季度财报